This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Sue Shapses, Rutgers University Identifier:
First received: June 30, 2011
Last updated: August 14, 2016
Last verified: August 2016
In this study, we will provide supplemental vitamin D in postmenopausal overweight/obese women, and hypothesize that it will not affect areal BMD, but will alter bone compartments (trabecular and cortical bone). In addition, higher vitamin D intake will increase serum 25OHD and suppress serum PTH and bone turnover during weight reduction. Secondary outcomes include the influence of vitamin D and weight loss on markers of insulin resistance and on cognitive tests of attention, learning, and memory.

Condition Intervention
Osteoporosis Dietary Supplement: 600 IU Vitamin D3 Dietary Supplement: 2000 IU Vitamin D3 Dietary Supplement: 4000 IU Vitamin D3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: A Pilot Dose Response Study to Vitamin D in Obesity and Weight Loss: Effect on Bone

Resource links provided by NLM:

Further study details as provided by Sue Shapses, Rutgers University:

Primary Outcome Measures:
  • Bone mineral density [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Bone turnover markers [ Time Frame: Baseline, 3 mo, 6mo, 12months ]
    Other key measures that will be used to evaluate the intervention include tests of insulin resistance and cognition Serum and urinary calcium are measured as safety markers

Enrollment: 81
Study Start Date: January 2010
Estimated Study Completion Date: December 2016
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 600 IU D3 Dietary Supplement: 600 IU Vitamin D3
Once daily
Active Comparator: 2000 IU D3 Dietary Supplement: 2000 IU Vitamin D3
Once daily
Active Comparator: 4000 IU D3 Dietary Supplement: 4000 IU Vitamin D3
Once daily


Ages Eligible for Study:   50 Years to 72 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index of 25-40 kg/m2,
  • Postmenopausal,
  • Age 50-72 years.

Exclusion Criteria:

  • Women who are taking any medication known to influence Ca or bone metabolism, or with evidence of diseases known to influence Ca metabolism (i.e. metabolic bone disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, or renal disease, a kidney stone in the last 5 yrs., significant cardiac disease, active malignancy or cancer therapy within the past year) are not eligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01631292

United States, New Jersey
Rutgers University- Thompson Hall
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Rutgers University
Principal Investigator: Sue Shapses, PhD Rutgers University
  More Information

Responsible Party: Sue Shapses, Professor, Rutgers University Identifier: NCT01631292     History of Changes
Other Study ID Numbers: BBGP201095157
Study First Received: June 30, 2011
Last Updated: August 14, 2016

Additional relevant MeSH terms:
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 25, 2017